glp 3 peptide retatrutide Reta (GLP-3) 20mg GLP-3 (Reta) 20mg - NextEdge

Description

P.et al (2024)

Key FDA guidance: Incremental weight loss (enobosarm + GLP-1 versus GLP-1 alone) is an acceptable primary endpoint for approval The 3 mg dose is appropriate for continued development FDA encouraged including younger patients, not just older populations Phase 2 QUALITY study data: 16 weeks of enobosarm in older patients taking semaglutide Preserved lean mass and burned additional fat mass Improved physical function During the maintenance period (12 weeks after semaglutide discontinuation), enobosarm prevented weight regain by 46% compared to placebo Next steps : Veru plans to initiate the Phase 2b PLATEAU trial in Q1 2026, enrolling approximately 180 patients (both older and younger) with obesity taking tirzepatide

Withaar C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, Sillje HHW, Schouten EM, et al

This guide is designed to fill that gap, offering clear, evidence-based strategies to help you navigate common challenges, maximize the medications benefits, and ensure your weight loss journey supports long-term health, muscle preservation, and metabolic resilience